- Current report filing (8-K)
April 27 2009 - 1:19PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or
15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 26, 2009
MABCURE INC.
(Exact name of registrant as specified in its charter)
Nevada
(State or other jurisdiction of
incorporation)
333-141131
(Commission File Number)
20-4907813
(IRS Employer Identification
No.)
De Schiervellaan 3/B1
Hasselt, Belgium 3500
(Address of principal executive offices and Zip Code)
+32 (487) 425303
(Registrant's telephone
number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is
intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a -12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d -2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e -4(c))
Item 5.02 Departure of Directors or Principal Officers;
Election of Directors; Appointment of Principal Officers
On April 26, 2009, the Board of
Directors of the Registrant approved the appointment of Dr. David S. Frank to
its Board of Directors.
Dr. Frank, age 64, is the
Managing Director of MEDx Associates, a consulting company in the field of
diagnostics. He also serves as the Chairman of the Board of Nehora Photonics
Ltd., a medical device company located in Israel. From 2007-2008, Dr. Frank
served as a faculty member at the LAHAV-Tel Aviv University Graduate School of
Business, where he taught Health Care Technology courses for bioscience
entrepreneurs. From 1995-2007, Dr Frank was the executive director of business
development at Ortho-Clinical Diagnostics, a Johnson & Johnson company. From
1982-1994, Dr Frank was the director of marketing and planning management at
Kodak Clinical Diagnostics (Eastman Kodak Company). In 1971, Dr. Frank received
a Ph.D. in biochemistry from Cornell University.
In connection with Dr. Franks
appointment to the Board of Directors, the Registrant entered into an at-will
directors agreement with Dr. Frank, whereby:
-
Dr. Frank will receive $4,000 annually for his services as Director.
-
Dr. Frank will receive an additional annual payment of $8,000 if he serves
as a member of a committee of the Board.
-
The Registrant undertook to grant Dr. Frank stock options to purchase
120,000 shares of the Registrants common stock at an exercise price of $1.00
per share. These options will vest on April 17, 2010, provided that Dr. Frank
continues to be a Director of the Registrant through the first anniversary of
his appointment.
There are no family relationships between any of our Directors
or executive officers.
SIGNATURES
Pursuant to the requirements of
the Securities Exchange Act of 1934, the Registrant has duly caused this report
to be signed on its behalf by the undersigned hereunto duly authorized.
|
MABCURE INC.
|
|
(Registrant)
|
|
|
|
|
|
|
|
By:
/s/ Dr. Amnon Gonenne
|
|
Dr. Amnon Gonenne
|
|
President and Chief
Executive Officer
|
Date: April 27, 2009
MabCure (CE) (USOTC:MBCI)
Historical Stock Chart
From Jun 2024 to Jul 2024
MabCure (CE) (USOTC:MBCI)
Historical Stock Chart
From Jul 2023 to Jul 2024